Partial
Not Aligned
Patient Risk:
Low
Summary
Claims provided are largely about availability/manufacturing and patient access, which are not addressed in the provided FDA label excerpts. Only the statement about access barriers resembles on-label language about effectiveness limitations (methadone), but that is not actually reflected in the claims. No dosing/contraindications/boxed warnings/specific safety claims were made, limiting label alignment assessment.
Category Scores
Accurate Statements
Unsupported Statements
Amitiza (lubiprostone) is still marketed in the U.S. as an active prescription drug.
The provided prescribing information excerpts do not state marketing status, discontinuation status, or current U.S. availability/manufacturing.
Amitiza (lubiprostone) is still being manufactured and supplied for patients in the U.S.
The provided prescribing information excerpts do not describe manufacturing or supply status in the U.S.
Generic lubiprostone is available.
The provided prescribing information excerpts do not mention generic availability.
Coverage or formulary changes can make Amitiza hard to get even if it is still manufactured.
The provided prescribing information excerpts do not discuss payer coverage/formulary effects on drug access.
Temporary supply limits can look like discontinuation.
The provided prescribing information excerpts do not address drug supply disruptions or how they may be perceived relative to discontinuation.
Contradictions
Important Omissions
No on-label clinical or safety/administration content was provided to evaluate against the prescribing information (e.g., indications, dosing, contraindications, warnings, adverse reactions).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims concern marketing/supply/access rather than prescribing instructions or safety (e.g., contraindications, warnings). Therefore, risk of misprescribing from these specific claims is not directly supported by the provided label excerpts; however, because they are unsupported by the label text, their factual reliability relative to the FDA label cannot be confirmed.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
The response makes multiple factual assertions about U.S. marketing/manufacturing/generic availability and payer access barriers that are not addressed in the provided FDA label excerpts.
Suggested Improvement
Restrict claims to information explicitly present in the prescribing information (e.g., indications, dosing, contraindications, warnings/precautions, adverse reactions, and labeled limitations such as opioid-diphenylheptane efficacy not established). Avoid stating current market/supply status or generic availability unless supported by the provided label text.